The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19): Remdesivir Is a Foot in the Door.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Favipiravir for treating COVID-19.The Cochrane database of systematic reviews · 2024
   Pooled it
2. Studying the clinical, radiological, histological, microbiological, and immunological evolution during the different COVID-19 disease stages using minimal invasive autopsy.Scientific reports · 2022
   Trial
3. Immunomodulatory therapies in community-acquired pneumonia: a protocol for a systematic review and network meta-analysis.BMJ open · 2025
   Article
4. COVID-19 related ICU admissions in paediatric and young adult patients in Australia: a national case series 2020-2022.The Lancet regional health. Western Pacific · 2023
   Article
5. Efficacy of the combination of monoclonal antibodies against the SARS-CoV-2 Beta and Delta variants.PloS one · 2023
   Article
6. Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023
   Article
7. Respiratory viruses: their importance and lessons learned from COVID-19.European respiratory review : an official journal of the European Respiratory Society · 2022
   Review
8. An autopsy case of COVID-19 with a sudden death: Clinico-pathological comparison.Clinical case reports · 2022
   Article
9. SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation.Frontiers in immunology · 2022
   Review
10. Unraveling Muscle Impairment Associated With COVID-19 and the Role of 3D Culture in Its Investigation.Frontiers in nutrition · 2022
    Review
11. Remdesivir: Quo vadis?Biochemical pharmacology · 2021
    Review
12. Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?Regenerative medicine · 2021
    Review
13. The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients.JMA journal · 2021
    Review
14. Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021
    Article
15. Prognostic factors in cancer patients infected with SARS-CoV-2: a Latin American country results.Therapeutic advances in chronic disease · 2021
    Article
16. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword.Frontiers in immunology
    Review

Corrections and comments

• Comment on
  Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.2021

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as